Table 4.
The antimicrobial susceptibility profiles of Salmonella isolates with different serotypes
| Antimicrobial agent | No. of resistant isolates by serotypes (resistant rate, %) | |||||
|---|---|---|---|---|---|---|
| Typhimurium (n = 85) |
Enteritidis (n = 29) |
London (n = 5) |
Senftenberg (n = 8) |
Others (n = 70) |
Total (n = 197) |
|
| Penicillins | ||||||
| ampicillin | 81 (95.3) | 22 (75.9) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 139 (70.6) |
| piperacillin | 74 (87.1) | 21 (72.4) | 2 (40.0) | 0 (0.0) | 30 (42.9) | 127 (64.5) |
| β-lactam/β-lactamase inhibitors | ||||||
| ampicillin/ sulbactam | 9 (10.6) | 7 (24.1) | 0 (0.0) | 1 (12.5) | 6 (8.6) | 23 (11.7) |
| Cephems | ||||||
| cefazolin | 50 (58.8) | 16 (55.2) | 1 (20.0) | 1 (12.5) | 19 (27.1) | 87 (44.2) |
| cefepime | 23 (27.1) | 5 (17.2) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 37 (18.8) |
| cefotaxime | 40 (47.1) | 8 (27.6) | 0 (0.0) | 1 (12.5) | 15 (21.4) | 64 (32.5) |
| ceftriaxone | 42 (49.4) | 9 (31.0) | 0 (0.0) | 1 (12.5) | 14 (20.0) | 66 (33.5) |
| cefoxitin | 3 (3.5) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 1 (1.4) | 7 (3.6) |
| ceftazidime | 13 (15.3) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 7 (10.0) | 23 (11.7) |
| Monobactams | ||||||
| aztreonam | 23 (27.1) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 9 (12.9) | 35 (17.8) |
| Aminoglycosides | ||||||
| gentamicin | 22 (25.9) | 0 (0.0) | 3 (60.0) | 0 (0.0) | 13 (18.6) | 38 (19.3) |
| amikacin | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
| streptomycin | 57 (67.1) | 20 (69.0) | 2 (40.0) | 1 (12.5) | 27 (38.6) | 107 (54.3) |
| Carbapenems | ||||||
| imipenem | 3 (3.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 4 (2.0) |
| meropenem | 2 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (1.0) |
| Tetracyclines | ||||||
| tetracycline | 81 (95.3) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 39 (55.7) | 125 (63.5) |
| Quinolones and Fluoroquinolones | ||||||
| ciprofloxacin | 7 (8.2) | 2 (6.9) | 2 (40.0) | 0 (0.0) | 8 (11.4) | 19 (9.6) |
| levofloxacin | 5 (5.9) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 6 (8.6) | 12 (6.1) |
| norfloxacin | 7 (8.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
| nalidixic acid | 26 (30.6) | 27 (93.1) | 3 (60.0) | 0 (0.0) | 18 (25.7) | 74 (37.6) |
| Folate pathway inhibitors | ||||||
| sulphamethoxazole/trimethoprim | 42 (49.4) | 4 (13.8) | 2 (40.0) | 1 (12.5) | 26 (37.1) | 75 (38.1) |
| trimethoprim | 38 (44.7) | 3 (10.3) | 2 (40.0) | 0 (0.0) | 22 (31.4) | 65 (33.0) |
| Phenicols | ||||||
| Chloramphenicol | 41 (48.2) | 2 (6.9) | 1 (20.0) | 0 (0.0) | 21 (30.0) | 65 (33.0) |
| Nitrofurans | ||||||
| nitrofurantoin | 2 (2.4) | 11 (37.9) | 0 (0.0) | 0 (0.0) | 8 (11.4) | 21 (10.7) |
| MAR index | ||||||
| <0.08 | 0 (0.0) | 3 (10.3) | 2 (40.0) | 6 (72.5) | 23 (32.9) | 34 (17.3) |
| 0.08- | 3 (3.5) | 3 (10.3) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 12 (6.1) |
| 0.13- | 5 (5.9) | 1 (3.4) | 1 (20.0) | 0 (0.0) | 3 (4.3) | 10 (5.1) |
| 0.17- | 10 (11.8) | 2 (6.9) | 0 (0.0) | 1 (12.5) | 5 (7.1) | 18 (9.1) |
| ≥0.21 | 67 (78.8) | 20 (69.0) | 2 (40.0) | 0 (0.0) | 34 (48.6) | 123 (62.4) |